共 2 条
- [1] Re: Karim Fizazi, Charles G. Drake, Tomasz M. Beer, et al. Final Analysis of the Ipilimumab Versus Placebo Following Radiotherapy Phase III Trial in Postdocetaxel Metastatic Castration-resistant Prostate Cancer Identifies an Excess of Long-term Survivors. Eur Urol 2020;78:822-830 Interpreting the Effect of Ipilimumab Following Radiotherapy for Patients with Postdocetaxel Metastatic Castration-resistant Prostate Cancer [J]. EUROPEAN UROLOGY, 2021, 79 (01) : E10 - E11